Princeton-based Covance, a drug development and nutritional analysis company, announced Wednesday it has appointed Dr. Robert Wasserman and Dr. Rogelio Mosqueda-Garcia to its clinical development services, scientific leadership team.
Wasserman has been appointed vice president and global therapeutic area head, oncology, and Mosqueda-Garcia is the new global vice president, early clinical services within medical and scientific affairs.
“With our appointment of these two respected and accomplished leaders in the pharmaceutical industry, we continue to grow Covance’s scientific and medical leadership and our expertise across critical therapeutic areas within drug development,” Dr. Ken Somberg, chief medical officer and vice president, clinical development services, said in a prepared statement. “Covance’s medical and scientific affairs team is well positioned to offer guidance and insights in key therapeutic categories such as oncology, where there is a growing number of targets and an emphasis on personalized medicine, as well as in the preclinical to proof-of-concept space, where the focus is on accelerating development, increasing quality and providing more robust data in the decision-making process.”
Wasserman has extensive experience in oncology translation medicine, according to a news release. In his new role, he will be responsible for leading the scientific strategy for oncology and hematology therapeutics. Prior to Covance, Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as its site head of academic alliances, pharma research and early development for the Translational Clinical Research Center. Before that, he was the vice president and personalized health care strategic expert for Roche pRED Oncology. In his early career, he held senior-level positions at Merck and Novartis.
“Covance enjoys a strong reputation for the depth and breadth of its experience serving clients in biotechnology and pharmaceuticals,” Wasserman said. “I look forward to working with Covance’s talented oncology team as well as the global medical and scientific community across the company.”
Mosqueda-Garcia is a clinical pharmacologist with extensive experience in several therapeutics, as well as in translational and experimental medicine. In his new role, he will help navigate scientific direction for the Clinical Pharmacology Services and Early Clinical Development groups. Prior to Covance, he was the executive director in clinical pharmacology at AstraZeneca Pharmaceuticals. Before that, he held senior-level positions at Bristol-Myers Squibb and DuPont Pharmaceuticals. Prior to joining the pharmaceutical industry, he was a faculty member at Vanderbilt University in the Clinical Pharmacology Division, Department of Medicine.
“Covance’s commitment to operational, scientific and service excellence ensures it will continue to grow and provide comprehensive solutions to clients,” Mosqueda-Garcia said. “I am very excited to join Covance and contribute to its future success in critical areas of early drug development.”
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy